Antimicrobial activity of daptomycin tested against Staphylococcus aureus with vancomycin MIC of 2 μg/mL isolated in the United States and European hospitals (2006–2008)

References 

1. Boucher HW, Sakoulas G. Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin. Infect. Dis. 2007;45:601–608
   • CrossRef
2. Clinical and Laboratory Standards Institute (CLSI) . Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard—eighth edition, M07-A8. Wayne, PA: CLSI; 2009;
3. Clinical and Laboratory Standards Institute (CLSI) . Performance standards for antimicrobial susceptibility testing: 19th informational supplement (M100-S19). Wayne, PA: CLSI; 2009;
4. Cubicin Package Insert . Available at http://www.cubicin.com/pdf/PrescribingInformation.pdf2009;Accessed on June 2009
5. Cui L, Tominaga E, Neoh HM, Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 2006;50:1079–1082
   • MEDLINE
   • CrossRef
6. Deresinski S. Vancomycin heteroresistance and methicillin-resistant Staphylococcus aureus. J. Infect. Dis. 2009;199:605–609
   • CrossRef
7. Howden BP, Ward PB, Charles PG, Korman TM, Fuller A, du Cros P, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin. Infect. Dis. 2004;38:521–528
   • CrossRef
8. Jones RN. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin. Infect. Dis. 2006;42(Suppl. 1):S13–S24
   • CrossRef
9. Leonard SN, Rossi KL, Newton KL, Rybak MJ. Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides. J. Antimicrob. Chemother. 2009;63:489–492
10. Maor Y, Hagin M, Belausov N, Keller N, Ben-David D, Rahav G. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus Bacteremia versus those of methicillin-resistant S. aureus bacteremia. J. Infect. Dis. 2009;199:619–624
    • CrossRef
11. Moody J, Knapp C. Tests to assess bactericidal activity. In:  Isenberg HD editors. Clinical microbiology procedures handbook. Washington, DC: ASM Press; 2004;p. 5.10.31–36
12. Neoh HM, Hori S, Komatsu M, Oguri T, Takeuchi F, Cui L, et al. Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections. Ann. Clin. Microbiol. Antimicrob. 2007;6:13
    • CrossRef
13. Sader HS, Jones RN. Antimicrobial susceptibility of Gram-positive bacteria isolated from United States medical centers: Result of the Daptomycin Surveillance Program (2007--2008). Diagn. Microbiol. Infect. Dis. 2009;65:158–162
    • Abstract
    • Full Text
    • Full-Text PDF (136 KB)
    • CrossRef
14. Sader HS, Moet GJ, Jones RN. Update of the In vitro activity of daptomycin tested 17,193 Gram-positive Bacteria isolated from European medical centers (2005-2007). J. Chemother. 2009;[In Press]
15. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 2004;42:2398–2402
    • MEDLINE
    • CrossRef